Pacer Advisors, Inc. Alnylam Pharmaceuticals, Inc. Transaction History

Pacer Advisors, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $25,222 - $43,472	176 Added 61.75%	461 $112,000
Q1 2024 May 10, 2024	BUY	$146.51 - $198.2 $41,755 - $56,487	285 New	285 $42,000
Q2 2021 Jul 21, 2021	SELL	$128.63 - $176.89 $70,746 - $97,289	-550 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$126.83 - $175.69 $59,863 - $82,925	-472 Reduced 46.18%	550 $78,000
Q4 2020 Jan 20, 2021	BUY	$122.97 - $147.0 $22,626 - $27,048	184 Added 21.96%	1,022 $133,000

Q3 2020 Oct 19, 2020	BUY	$121.19 - $165.49 $101,557 - $138,680	838 New	838 $122,000
Q4 2018 Feb 13, 2019	SELL	$62.67 - $88.33 $165,448 - $233,191	-2,640 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $231,052 - $323,848	2,640 New	2,640 $231,000
Q1 2018 May 14, 2018	SELL	$115.92 - $148.54 $176,778 - $226,523	-1,525 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $1.17 Million - $1.43 Million	-10,241 Reduced 87.04%	1,525 $194,000
Q3 2017 Nov 08, 2017	BUY	$72.53 - $118.27 $853,387 - $1.39 Million	11,766	11,766 $1.38 Million

921

117M

1.25M

1.49M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.